Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4975230 | 0.91 | HSP90AB1 (0.45) | HPGDMAPTALOX15HSD17B10KDM4E | |
| SCHEMBL4978678 | 0.91 | HRH3 (0.44) | MAPTHSP90AA1HSP90AB1HRH3OGA | |
| SCHEMBL4980657 | 0.89 | MAPT (0.39) | HPGDMAPTALOX15HSD17B10KDM4E | |
| SCHEMBL4976501 | 0.89 | MEN1 (0.45) | PTPN11HPGDMAPTKMT2AHCRTR1 | |
| SCHEMBL4974605 | 0.88 | ALDH1A1 (0.46) | PTPN11HPGDMAPTALDH1A1KMT2A | |
| SCHEMBL4978182 | 0.86 | LMNA (0.46) | MAPTALDH1A1KMT2AHCRTR1HCRTR2 | |
| SCHEMBL4978771 | 0.85 | HSP90AA1 (0.46) | PTPN11MAPTHCRTR1HCRTR2HSP90AA1 | |
| SCHEMBL4979714 | 0.85 | PTPN11 (0.42) | PTPN11MAPTALDH1A1KMT2AHCRTR1 | |
| SCHEMBL4980323 | 0.84 | PTPN11 (0.45) | PTPN11MAPTKDM4EALDH1A1HCRTR1 | |
| SCHEMBL4980624 | 0.83 | ALDH1A1 (0.49) | HPGDMAPTALDH1A1KMT2AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | PTPN11 4015/4885HPGD 159/4885MAPT 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.